Novo Nordisk E-Detailing Strategy Infiltrates China County Hospital Market
This article was originally published in PharmAsia News
County hospitals are leading health care growth in China, but costs are high and profitability low. Armed with mobile technologies, Novo Nordisk has forged ahead with education and commercial pilot efforts that have brought measures of success and surprises along the way, Jack Chen, China marketing vice president, tells PharmAsia News.
You may also be interested in...
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.